A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
REGULATORY
LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
Amid soaring manufacturing costs and wage hikes in the pharma industry, calls have been growing among Liberal Democratic Party (LDP) lawmakers for scrapping the de-facto budget cap on social security spending. Japan should allow not only a cost increase linked…
To read the full story
Related Article
- LDP Study Group Submits Proposal for FY2024 Reform, Urges Boosted Drug Price Premiums at Launch
November 21, 2023
- LDP Pharma Study Group Calls for Expanding Sakigake Premium, Creating New Premium
November 15, 2023
- Honebuto Policy Is Tailwind for Pharma, but Situation Remains Unpredictable
June 22, 2023
- Japan OKs Honebuto Budget Policy Blueprint, Vows Debates on Longer-Term Drug Costs
June 19, 2023
- LDP Policy Research Council Generally Approves Revised Honebuto Draft
June 14, 2023
- Honebuto Social Security Debate Culminates with LDP Push for Nixing Budget Cap
June 9, 2023
- LDP Pharma Study Group Proposes Removing Cap for Social Security Costs
May 23, 2023
- LDP Pharma Study Group to Draw Up Resolution in May before Honebuto Paper
April 13, 2023
REGULATORY
- Drug Discovery Fund Not Mentioned in Ruling Party Document; All Eyes on Bill’s Review on Jan. 27
January 24, 2025
- MHLW Eyes 2 Biz Models as It Pushes Generic Industry Shakeup: Minister
January 23, 2025
- Draft Bill to Amend PMD Act Up for LDP Review on Jan. 27
January 23, 2025
- How’s Drug Discovery Fund Different from AMED? LDP Member Says It’s Too Early to Submit Legislation
January 22, 2025
- Astellas’ Xtandi on 2nd Drug List Up for IRA Price Negotiations
January 21, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…